Mitesco (MITI) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 12, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Information [Line Items]
Entity Registrant Name	MITESCO, INC.
Entity Central Index Key	0000802257
Entity File Number	000-53601
Entity Tax Identification Number	87-0496850
Entity Incorporation, State or Country Code	NV
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	505 Beachland Blvd., Suite 1377
Entity Address, City or Town	Vero Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32963
Entity Phone Fax Numbers [Line Items]
City Area Code	844
Local Phone Number	844-383-8689
Entity Listings [Line Items]
Entity Common Stock, Shares Outstanding		5,935,044

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 40,785	$ 2,838
Prepaids and other current assets	15,000	0
Total current assets	55,785	2,838
Total assets	55,785	2,838
Current liabilities:
Accounts payable and accrued liabilities	7,393,234	7,838,112
Derivative liabilities	152,945	152,945
Lease liability - operating lease, current	99,477	99,477
SBA loan payable	414,002	421,788
Other current liabilities	96,136	121,136
Legal settlements	2,452,768	2,219,886
Total current liabilities	14,726,727	14,134,595
Total liabilities	14,726,727	14,134,595
Stockholders' equity (deficit)
Common stock, $0.01 par value, 500,000,000 shares authorized, 5,634,027 and 5,567,957 shares issued and outstanding as of March 31, 2024 and December 31, 2023 , respectively	56,341	55,680
Additional paid-in capital	47,270,074	47,856,444
Accumulated deficit	(62,000,300)	(62,046,824)
Total stockholders' equity (deficit)	(14,670,942)	(14,131,757)
Total liabilities and stockholders' equity (deficit)	55,785	2,838
Series A Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred stock, Value	0	0
Series C Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred stock, Value	0	0
Series D Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred stock, Value	2,500	2,500
Series F Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred stock, Value	201	201
Series X Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred stock, Value	242	242
Nonrelated Party [Member]
Current liabilities:
Accrued interest	389,444	348,821
Notes payable, net of discounts	1,145,429	945,429
Preferred stock dividends payable	2,049,289	1,551,833
Related Party [Member]
Current liabilities:
Accrued interest	72,374	61,792
Notes payable, net of discounts	300,012	300,012
Preferred stock dividends payable	$ 161,617	$ 73,364

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	5,634,027	5,567,957
Common stock, shares outstanding	5,634,027	5,567,957
Series A Preferred Stock [Member]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series C Preferred Stock [Member]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series D Preferred Stock [Member]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued	250,000	250,000
Preferred stock, shares outstanding	250,000	250,000
Series F Preferred Stock [Member]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued	20,057	20,057
Preferred stock, shares outstanding	20,057	20,057
Series X Preferred Stock [Member]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued	24,227	24,227
Preferred stock, shares outstanding	24,227	24,227

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
General and administrative	$ 135,476	$ 1,629,903
Impairment of fixed assets	0	128,465
Total operating expenses	135,476	1,758,368
Net loss from operations	(135,476)	(1,758,368)
OTHER INCOME (EXPENSES):
Gain on termination of operating lease	233,205	0
(Loss) Gain on revaluation of derivative liabilities	0	(110,778)
Total other income (expense)	182,000	(1,530,413)
Net income (loss) from continuing operations	46,524	(3,288,781)
Net loss from discontinued operations	0	(2,325,044)
Consolidated net income (loss)	46,524	(5,613,825)
Preferred stock dividends	(638,565)	(79,818)
Net loss available to common shareholders	$ (592,041)	$ (5,693,644)
Net loss per common share - continuing operations (in Dollars per share)	$ (0.11)	$ (0.7)
Net loss per common share - discontinued operations (in Dollars per share)	0	(0.48)
Net loss per common share (in Dollars per share)	$ (0.11)	$ (1.18)
Weighted average shares outstanding (in Shares)	5,593,991	4,825,054
Nonrelated Party [Member]
OTHER INCOME (EXPENSES):
Interest expense	$ (46,130)	$ (1,376,066)
Preferred stock dividends	(550,312)	(61,823)
Related Party [Member]
OTHER INCOME (EXPENSES):
Interest expense	(5,075)	(43,569)
Preferred stock dividends	$ (88,253)	$ (17,996)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)	Convertible Debt [Member] Common Stock [Member]	Convertible Debt [Member] AOCI Attributable to Parent [Member]	Convertible Debt [Member]	Series D Preferred Stock [Member] Preferred Stock [Member]	Series D Preferred Stock [Member]	Series F Preferred Stock [Member] Preferred Stock [Member]	Series F Preferred Stock [Member]	Series X Preferred Stock [Member] Preferred Stock [Member]	Series X Preferred Stock [Member] Common Stock [Member] Stock issued for dividends payable [Member]	Series X Preferred Stock [Member] AOCI Attributable to Parent [Member] Stock issued for dividends payable [Member]	Series X Preferred Stock [Member] Stock issued for dividends payable [Member]	Series X Preferred Stock [Member]	Series C Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Stock Subscribed [Member]	Total
Balance at Dec. 31, 2022				$ 31,000				$ 242					$ 10,476	$ 46,305	$ 29,452,514	$ (48,714,461)	$ 36,575	$ (19,137,349)
Balance (in Shares) at Dec. 31, 2022				3,100,000				24,227					1,047,619	4,630,372
Shares issued for conversion of note payable	$ 571	$ 82,885	$ 83,456
Shares issued for conversion of note payable (in Shares)	57,138
Vesting of stock options issued to employees															933			933
Shares issued to service providers														$ 3,000	894,000			897,000
Shares issued to service providers (in Shares)														300,000
Shares issued for Series X dividends									$ 81	$ 35,248	$ 35,329
Shares issued for Series X dividends (in Shares)									8,063
Preferred stock dividends															(79,818)			(79,818)
Net income (loss)																(5,613,825)		(5,613,825)
Balance at Mar. 31, 2023				$ 31,000				$ 242					$ 10,476	$ 49,957	30,385,762	(54,328,286)	$ 36,575	(23,814,274)
Balance (in Shares) at Mar. 31, 2023				3,100,000				24,227					1,047,619	4,995,573
Balance at Dec. 31, 2023				$ 2,500		$ 201		$ 242						$ 55,680	47,856,444	(62,046,824)		$ (14,131,757)
Balance (in Shares) at Dec. 31, 2023				250,000		20,057		24,227						5,567,957
Shares issued for Series X dividends									$ 661	$ 52,195	$ 52,856
Shares issued for Series X dividends (in Shares)									66,070									66,070
Preferred stock dividends					$ (3,928)		$ (608,393)					$ (26,244)			(638,565)			$ (638,565)
Net income (loss)																46,524		46,524
Balance at Mar. 31, 2024				$ 2,500		$ 201		$ 242						$ 56,341	$ 47,270,074	$ (62,000,300)		$ (14,670,942)
Balance (in Shares) at Mar. 31, 2024				250,000		20,057		24,227						5,634,027

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOW - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net income (loss)	$ 46,524	$ (3,288,781)
Adjustments to reconcile net income(loss) to net cash provided by (used in) operating activities:
Impairment of right of use asset	0	83,810
Depreciation expense	0	11,393
Penalties on notes payable	0	1,102,778
Share based compensation	0	897,933
Gain (loss) on lease terminations	(233,205)	0
Gain (loss) on revaluation of derivative liabilities	0	110,778
Changes in operating assets and liabilities:
Prepaid expenses	(15,000)	(8,198)
Accounts payable and accrued liabilities	21,209	501,998
Other current liabilities	(25,000)	25,000
Net cash used in operating activities from continuing operations	(154,267)	(338,126)
Net cash provided by operating activities from discontinued operations	0	302,802
Net cash provided by (used in) operating activities	(154,267)	(35,324)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on SBA Loan	(7,786)	0
Proceeds from notes payable, net of discounts	200,000	0
Net cash provided by financing activities from continuing operations	192,214	0
Net cash provided by financing activities from discontinued operations	0	0
Net cash provided by financing activities	192,214	0
Net change in cash	37,947	(35,324)
Cash at beginning of period	2,838	35,623
Cash at end of period	40,785	299
Supplemental disclosure of cash flow information:
Cash paid for interest	0	0
Cash paid for taxes	0	0
Supplemental disclosure of financing cash flow information:
Preferred stock dividends	638,565	79,818
Discount on notes payable due to warrants	0	94,672
Increase in capital expenditures included in accounts payable	0	109,383
Shares issued for Series X dividends	52,856	0
Stock Subscribed [Member]
Supplemental disclosure of financing cash flow information:
Stock Issued for common stock subscribed	0	83,456
Nonrelated Party [Member]
Adjustments to reconcile net income(loss) to net cash provided by (used in) operating activities:
Amortization of discount on notes payable	0	23,538
Changes in operating assets and liabilities:
Accrued interest	40,623	163,770
Supplemental disclosure of financing cash flow information:
Preferred stock dividends	550,312	61,823
Related Party [Member]
Adjustments to reconcile net income(loss) to net cash provided by (used in) operating activities:
Amortization of discount on notes payable	0	11,131
Changes in operating assets and liabilities:
Accrued interest	10,582	26,724
Supplemental disclosure of financing cash flow information:
Preferred stock dividends	$ 88,253	$ 17,996

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1: Description of Business Company Overview Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we completed a “spin out” of our former business line. On April 24, 2020, we changed our name to Mitesco, Inc. In October 2023, the Company completed a move of its corporate status to Nevada from Delaware in order to effect reduced costs. The details can be found at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000802257/000118518523001074/mitesco20231016_8k.htm From 2020 through 2022, our operations were focused on establishing medical clinics utilizing Nurse Practitioners under The Good Clinic name and development and acquisition of telemedicine technology. We opened our first The Good Clinic in Minneapolis, Minnesota in the first quarter of 2021 and had six operating clinics during the year ended December 31, 2022, with two additional sites under contract. In the fourth quarter of fiscal 2022, we made the strategic decision to close the entire clinic operation and release our staff due to a lack of profitability. We are a holding company seeking to provide products, services and technology. We have a number of near-term opportunities that we hope to pursue, assuming the capital markets make sufficient funding available at reasonable rates. During the first quarter of 2024 we recruited a number of individuals to a newly formed Advisory Board, who might assist the Company in determining the viability of certain ventures going forward. These individuals have a background in data center services, cyber and data security and software applications related to infrastructure design, implementation and management including geographical information systems (GIS). We expect to announce in the second quarter of 2024 the formation of a new, wholly owned subsidiary whose business will be focused on those areas generally.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	Note 2: Going Concern As of March 31, 2024, the Company had cash and cash equivalents of approximately $41,000, current liabilities of approximately $14.7 million, and has incurred significant losses from the previous clinic operations. As previously noted, we made a strategic decision to reduce our capital needs by closing our entire clinic operations in the fourth quarter of 2022 and releasing our entire staff, due to lack of profitability. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan. As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern for one year from the date the financial statements are issued. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. However, as of the date of these consolidated financial statements, no formal agreement exists. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions. The COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company’s business and the value of its common stock.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 3: Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements and related disclosures as of March 31, 2024 are unaudited, pursuant to the rules and regulations of the United States Securities and Exchange Commission (“ SEC Principles of Consolidation Per Share Data - Discontinued Operations - Presentation of Financial Statements Property, Plant and Equipment Recent Accounting Standards ASU 2023-07 Segment Reporting ( Topic 280 Improvements to Reportable Segment Disclosures, In December 2023, the FASB issued ASU 2023-09 Income Taxes ( Topic 740 Improvements to Income Tax Disclosures, There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Note 4: Discontinued Operations In the fourth quarter of fiscal 2022, we made the strategic decision to close the entire clinic operation and release our staff due to a lack of profitability. On December 8, 2023, the Company sold the remaining assets of The Good Clinic, LLC to Leading Primary Care LLC, a company organized by Michael C. Howe, the former CEO of The Good Clinic, LLC for total consideration of approximately $2.5 million. ASC 360-10-45-9 requires that a long-lived asset (disposal group) to be sold shall be classified as held for sale in the period in which a set of criteria have been met, including criteria that the sale of the asset (disposal group) is probable and actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. This criteria was achieved on December 8, 2023. Additionally, the discontinued operations are comprised of the entirety of The Good Clinic, LLC. For comparability purposes certain prior period line items relating to the assets held for sale have been reclassified and presented as discontinued operations for all periods presented in the accompanying consolidated statements of net loss and comprehensive loss and the consolidated balance sheets. The Company had no assets or liabilities classified that were classified as held as part of discontinued operations as of March 31, 2024 or December 31, 2023. The following information presents the major classes of line items constituting the after-tax loss from discontinued operations in the consolidated statements of operations: Three Months Ended March 31, March 31, 2024 2023 Revenue $ - $ - Cost of goods sold - 2,419 Gross margin - (2,419 ) Selling, general, and administrative expenses - (381,501 ) Impairment of assets - (2,143,428 ) Other (income) expense: Gain on termination of operating lease - 287,897 Interest expense - (85,593 ) Loss from discontinued operations, net of tax $ - $ (2,325,044 ) The following information presents the major classes of line items constituting significant operating and investing cash flow activities in the consolidated statements of cash flows relating to discontinued operations: Three Months Ended March 31, March 31, 2024 2023 Depreciation expense $ - $ 33,262 Impairment of property and equipment $ - $ 2,271,893 Changes in accounts payable and accrued liabilities $ - $ 549,929

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 5: Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consisted of the following at March 31, 2024 and December 31, 2023: March 31, December 31, 2024 2023 Trade accounts payable $ 6,604,738 $ 7,094,334 Accrued payroll and payroll taxes 788,496 743,778 Total accounts payable and accrued liabilities $ 7,393,234 $ 7,838,112

Right to Use Assets and Lease L

Right to Use Assets and Lease Liabilities – Operating Leases	3 Months Ended
	Mar. 31, 2024
Disclosure Text Block [Abstract]
Lessee, Operating Leases [Text Block]	Note 6: Right to Use Assets and Lease Liabilities Operating Leases The Company had operating leases for its clinics for which the Company is currently in negotiations with the Lessors to settle the remaining amounts owed after closing the clinic facilities. The Company’s lease expense was entirely comprised of operating leases and is reported as a component of discontinued operations as a result of closing of the clinics and the subsequent sale of the assets. As of December 31, 2023, the Company had impaired all balances of the related right to use assets. Operating lease liabilities are summarized below: March 31, 2024 December 31, 2023 Lease liability $ 99,477 $ 99,477 Less: current portion (99,477 ) (99,477 ) Lease liability, non-current $ - $ - As a result of closing the facilities, the Company has made no further lease payments during the year ending December 31, 2023 or the three months ended March 31, 2024. As of March 31, 2024 the Company has either settled amounts owed or entered in into default judgements for all leases except for the office lease. For all leases for which a legal settlement have been entered into, all amounts have been reclassified to legal settlements as of March 31, 2024 and December 31, 2023. For the period ended December 31, 2024 $ 99,477 For the period ended December 31, 2025 - For the period ended December 31, 2026 - For the period ended December 31, 2027 - For the period ended December 31, 2028 - Thereafter - Total $ 99,477 Less: Present value discount - Lease liability $ 99,477 As of December 31, 2023, the Company has entered into settlement agreements for certain of our leases in the amount of $2,219,886 which is recorded as Legal Settlements Legal Settlements

SBA Loan Payable

SBA Loan Payable	3 Months Ended
	Mar. 31, 2024
Small Business Administration Loan Payable Abstract
Small Business Administration Loan Payable [Text Block]	Note 7: SBA Loan Payable PPP Loan Conversion to SBA Loan During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration (the “SBA”). On April 25, 2020, the Company entered an unsecured Promissory Note with Bank of America for a loan in the original principal amount of $460,400, and the Company received the full amount of the loan proceeds on May 4, 2020 (the “PPP Loan”). The PPP Loan bears interest at the rate of 1% per year. On July 12, 2023, the Company received confirmation of a payment plan arrangement from the SBA. Pursuant to this payment plan, the Company agreed to pay a minimum of $2,595 each month until the loan is paid in full in July 2028. The SBA confirmed the balance due on the loan, including principal and interest, was $467,117. The Company will amortize the balance due on the loan including interest at the original PPP loan rate of 1% per annum; a gain on restructure of debt in the amount of $40,622 was recorded on this transaction during the year ended December 31, 2023, and the balance of the loan was recorded at the amount of $433,343 representing the net cash flows discounted at 1%. During the three months ended March 31, 2024, the Company made principal payments of $7,786 on this loan and recorded interest in the amount of $1,052.

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2024
Notes Payable [Line Items]
Debt Disclosure [Text Block]	Note 8: Notes Payable The following table summarizes the outstanding notes payable as of March 31, 2024 and December 31, 2023, respectively: March 31, 2024 December 31, 2023 Kishon Note $ 431,666 $ 431,666 Finnegan Note 1 51,765 51,765 Finnegan Note 2 32,353 32,353 Schrier Note 25,882 25,882 Nommsen Note 64,705 64,705 Caplan Note 64,705 64,705 Finnegan Note 3 32,353 32,353 Lightmas Note 66,000 66,000 Lewis Note 33,000 33,000 Goff Note 33,000 33,000 Hagan Note 110,000 110,000 Cavalry Note 1 25,000 - Cavalry Note 2 50,000 - Mercer Note 1 25,000 - Mercer Note 2 50,000 - ABJ Note 50,000 - Notes Payable $ 1,142,429 $ 945,429 Current Portion $ 1,145,429 $ 945,429 Long-term portion $ - $ - Kishon Note On May 10, 2022, the Company entered into a Securities Purchase Agreement (the “Kishon Agreement”) with Kishon Investments, LLC (“Kishon”) with respect to the sale and issuance to Kishon of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “Kishon Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “Kishon Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “Kishon Warrants”). Should Kishon receive net proceeds of less than $159,259 from the sale of the Kishon Commitment Fee Shares, the Company will issue additional shares to Kishon or pay the shortfall amount to Kishon in cash. The terms of the Kishon Agreement resulted in the Company recording a derivative liability in the initial amount of $27,793. The Kishon Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The Kishon Note has a due date of November 10, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Kishon Note this rate will increase to 18%, and the Kishon Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Kishon Note entered default status on November 11, 2022. The Kishon Commitment Fee Shares and Kishon Warrants resulted in a discount to the Kishon Note in the amount of $138,492. During the year ended December 31, 2023, a default penalty in the amount of $138,889 and an additional fee in the amount of $15,000 were added to the principal amount of the Kishon Note. At December 31, 2023, principal and interest in the amount of $431,666 and $88,909, respectively, were due on the Kishon Note. At March 31, 2024, principal and interest in the amount of $431,666 and $108,281, respectively, were due on the Kishon Note. This note was in default at March 31, 2024. Finnegan Note 1 On May 23, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 to Jessica Finnegan (the “Finnegan Note 1”). The Finnegan Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 20, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 1 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 1 entered default status on November 21, 2022, and the interest rate increased to 18%. The Finnegan Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 1, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 1. In addition, Ms. Finnegan received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,000 at the date of issuance, and 1,930 shares of common stock with a value of $3,240; these amounts were recorded as discounts to the Finnegan Note 1. Principal and accrued interest in the amount of $51,765 and $11,889, respectively, were due on this note at December 31, 2023. At March 31, 2024, principal and interest in the amount of $51,765 and $14,030, respectively, were due on the Kishon Note. This note was in default at March 31, 2024. Finnegan Note 2 On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 to Jessica Finnegan (the “Finnegan Note 2”). The Finnegan Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 2 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Finnegan Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 2, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 2. In addition, Ms. Finnegan received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $1,250 at the date of issuance, and 242 shares of common stock with a value of $2,025; these amounts were recorded as discounts to the Finnegan Note 2. At December 31, 2023principal and accrued interest in the amount of $32,353 and $7,341, respectively, were due on this note. At March 31, 2024, principal and interest in the amount of $32,353 and $8,679, respectively, were due on the Kishon Note. This note was in default at March 31, 2024. Schrier Note On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $23,259 to Charles Schrier (the “Schrier Note”). The Schrier Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 8, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Schrier Note was $20,000; the amount payable at maturity will be $23,529 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Schrier Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Schrier Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Schrier reasonably believes contains a term that is more favorable than those in the Schrier Note, the Company shall notify Mr. Schrier of such term, and such term, at the option of Mr. Schrier, shall become a part of the Schrier Note. In addition, Mr. Schrier received five-year warrants to purchase 193 shares of common stock at a price of $25.00 per share with a fair value of $820 at the date of issuance, and 193 shares of common stock with a value of $1,000; these amounts were recorded as discounts to the Schrier Note. At December 31, 2023, principal and accrued interest in the amount of $25,882 and $5,383, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $25,882 and $6,454, respectively, were due on this note. This note was in default at March 31, 2024. Nommsen Note On July 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Eric S. Nommsen (the “Nommsen Note”). The Nommsen Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Nommsen Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Nommsen Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Nommsen Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Nommsen Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Nommsen reasonably believes contains a term that is more favorable than those in the Nommsen Note, the Company shall notify Mr. Nommsen of such term, and such term, at the option of Mr. Nommsen, shall become a part of the Nommsen Note. In addition, Mr. Nommsen received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Nommsen Note. At December 31, 2023, principal and accrued interest in the amount of $64,705 and $13,685, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $64,705 and $16,361, respectively, were due on this note. This note was in default at March 31, 2024. Caplan Note On July 27, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to James H. Caplan (the “Caplan Note”). The Caplan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Caplan Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Caplan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Caplan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Caplan reasonably believes contains a term that is more favorable than those in the Caplan Note, the Company shall notify Mr. Caplan of such term, and such term, at the option of Mr. Caplan, shall become a part of the Caplan Note. In addition, Mr. Caplan received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Caplan Note. At December 31, 2023, principal and accrued interest in the amount of $64,705 and $12,989, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $64,705 and $15,665, respectively, were due on this note This note was in default at March 31, 2024. Finnegan Note 3 On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 (the “Finnegan Note 3”) to Jessica, Kevin C., Brody, Isabella and Jack Finnegan (collectively, the “Finnegans”). The Finnegan Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 3 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which The Finnegans reasonably believes contains a term that is more favorable than those in the Finnegan Note 3, the Company shall notify The Finnegans of such term, and such term, at the option of The Finnegans, shall become a part of the Finnegan Note 3. In addition, The Finnegans received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $850 at the date of issuance, and 242 shares of common stock with a value of $1,100; these amounts were recorded as discounts to the Finnegan Note 3. At December 31, 2023, principal and accrued interest in the amount of $32,353 and $6,350, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $32,353 and $7,688, respectively, were due on this note. This note was in default at March 31, 2024. Lightmas Note On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $60,000 to Frank Lightmas (the “Lightmas Note”). The Lightmas Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lightmas Note was $51,000; the amount payable at maturity will be $60,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lightmas Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lightmas Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lightmas Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Lightmas reasonably believes contains a term that is more favorable than those in the Lightmas Note, the Company shall notify Mr. Lightmas of such term, and such term, at the option of Mr. Lightmas, shall become a part of the Lightmas Note. In addition, Mr. Lightmas received 492 shares of common stock with a value of $2,640; this amount was recorded as a discount to the Lightmas Note. At December 31, 2023, principal and accrued interest in the amount of $66,000 and $13,325, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $66,000 and $16,055, respectively, were due on this note. This note was in default at March 31, 2024. Lewis Note On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Lisa Lewis (the “Lewis Note”). The Lewis Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lewis Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lewis Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lewis Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lewis Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lewis reasonably believes contains a term that is more favorable than those in the Lewis Note, the Company shall notify Ms. Lewis of such term, and such term, at the option of Ms. Lewis, shall become a part of the Lewis Note. In addition, Ms. Lewis received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Lewis Note. At December 31, 2023, principal and accrued interest in the amount of $33,000 and $6,663, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $33,000 and $8,028, respectively, were due on this note. This note was in default at March 31, 2024. Goff Note On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Sharon Goff (the “Goff Note”). The Goff Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Goff Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Goff Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Goff Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Goff Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Goff reasonably believes contains a term that is more favorable than those in the Goff Note, the Company shall notify Ms. Goff of such term, and such term, at the option of Ms. Goff, shall become a part of the Goff Note. In addition, Ms. Goff received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Goff Note. At December 31, 2023, principal and accrued interest in the amount of $33,000 and $6,663, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $33,000 and $8,028, respectively, were due on this note. This note was in default at March 31, 2024. Hagan Note On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $100,000 to Cliff Hagan (the “Hagan Note”). The Hagan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 10, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Hagan Note was $85,000; the amount payable at maturity will be $100,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Hagan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Hagan Note entered default status on December 11, 2022, and the interest rate increased to 18%. The Hagan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Hagan reasonably believes contains a term that is more favorable than those in the Hagan Note, the Company shall notify Mr. Hagan of such term, and such term, at the option of Mr. Hagan, shall become a part of the Hagan Note. In addition, Mr. Hagan received 820 shares of common stock with a value of $4,715; this amount was recorded as a discount to the Hagan Note. At December 31, 2023, principal and accrued interest in the amount of $110,000 and $21,793, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $110,000 and $26,343, respectively, were due on this note. This note was in default at March 31, 2024. Cavalry 2024 Note 1 On January 23, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to the Cavalry Fund LLP (“Cavalry”), (the “Cavalry Note 1”) with a due date of January 23, 2025. The Cavalry Note 1 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%. At March 31, 2024, principal and accrued interest in the amount of $25,000 and $465, respectively, were due on this note. Cavalry 2024 Note 2 On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to the Cavalry, (the “Cavalry Note 2”) with a due date of February 28, 2025. The Cavalry Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%. At March 31, 2024, principal and accrued interest in the amount of $50,000 and $431, respectively, were due on this note. Mercer 2024 Note 1 On January 23, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to the Mercer Street Global Opportunity Fund (“Mercer”), (the “Mercer Note 1”) with a due date of January 23, 2025. The Mercer Note bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%. At March 31, 2024, principal and accrued interest in the amount of $25,000 and $465, respectively, were due on this note. Mercer 2024 Note 2 On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Mercer, (the “Mercer Note 2”) with a due date of February 28, 2025. The Mercer Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Mercer Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%. At March 31, 2024, principal and accrued interest in the amount of $50,000 and $431, respectively, were due on this note. AJB 2024 Note On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to the AJB Capital Investments, LLC (“AJB”), (the “AJB Note”) with a due date of February 28, 2025. The AJB Note bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Mercer Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%. At March 31, 2024, principal and accrued interest in the amount of $50,000 and $431, respectively, were due on this note. Aggregate interest expense on the above notes payable was $40,624 for the three months ended March 31, 2024. Accrued interest on notes payable was $389,444 and $348,821 at March 31, 2024 and December 31, 2023, respectively.
Related Party [Member]
Notes Payable [Line Items]
Debt Disclosure [Text Block]	Note 9: Notes Payable Related Parties The following table summarizes the outstanding related party notes payable as of March 31, 2024 and December 31, 2023, respectively March 31, 2024 December 31, 2023 M Diamond Note 64,706 64,706 Dobbertin Note 19,412 19,412 Lindstrom Note 45,294 45,294 Mitchell Note 78,100 78,100 Leath Note 55,000 55,000 November 29, 2022 Notes 37,500 37,500 Notes Payable 300,012 300,012 Current Portion, net of discount $ 300,012 $ 300,012 Long-term portion, net of discount $ - $ - M Diamond Note On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Melissa Diamond (the “M Diamond Note”). Ms. Diamond is the daughter of Larry Diamond, former CEO. The M Diamond Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the M Diamond Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the M Diamond Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The M Diamond Note entered default status on December 1, 2022, and the interest rate increased to 18%. The M Diamond Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Diamond reasonably believes contains a term that is more favorable than those in the M Diamond Note, the Company shall notify Ms. Diamond of such term, and such term, at the option of Ms. Diamond, shall become a part of the M Diamond Note. In addition, Ms. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the M Diamond Note. At December 31, 2023, principal and accrued interest in the amount of $64,706 and $14,682, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $64,706 and $16,169, respectively, were due on this note. This note was in default at March 31, 2024. Dobbertin Note On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $17,647 in a related party transaction to Alexander Dobbertin (the “Dobbertin Note”). Mr. Dobbertin is the spouse of Jenny Lindstrom, who was the Company’s Chief Legal Officer. The Dobbertin Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dobbertin Note was $15,000; the amount payable at maturity will be $17,647 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Dobbertin Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dobbertin Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Dobbertin Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Dobbertin reasonably believes contains a term that is more favorable than those in the Dobbertin Note, the Company shall notify Mr. Dobbertin of such term, and such term, at the option of Mr. Dobbertin, shall become a part of the Dobbertin Note. In addition, Mr. Dobbertin received five-year warrants to purchase 145 shares of common stock at a price of $25.00 per share with a fair value of $750 at the date of issuance, and 145 shares of common stock with a value of $1,215; these amounts were recorded as discounts to the Dobbertin Note. At December 31, 2023 principal and accrued interest in the amount of $19,412 and $4,405, respectively, were due on this note. At March 31, 2024 principal and accrued interest in the amount of $19,412 and $5,197, respectively, were due on this note. This note was in default at March 31, 2024. Lindstrom Note On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $41,176 in a related party transaction to Jenny Lindstrom, who was the Company’s Chief Legal Officer (the “Lindstrom Note 1”). The Lindstrom Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lindstrom Note 1 was $35,000; the amount payable at maturity will be $41,176 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lindstrom Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lindstrom Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Lindstrom Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lindstrom reasonably believes contains a term that is more favorable than those in the Lindstrom Note 1, the Company shall notify Ms. Lindstrom of such term, and such term, at the option of Ms. Lindstrom, shall become a part of the Lindstrom Note 1. In addition, Ms. Lindstrom received five-year warrants to purchase 338 shares of common stock at a price of $25.00 per share with a fair value of $1,750 at the date of issuance, and 338 shares of common stock with a value of $2,835; these amounts were recorded as discounts to the Lindstrom Note 1. At December 31, 2023, principal and accrued interest in the amount of $45,294 and $10,277, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $45,294 and $12,125, respectively, were due on this note. This note was in default at March 31, 2024. Mitchell Note On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $71,000 to John Mitchell (the “Mitchell Note”). The Mitchell Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mitchell Note was $60,350; the amount payable at maturity will be $71,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mitchell Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mitchell Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Mitchell Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Mitchell reasonably believes contains a term that is more favorable than those in the Mitchell Note, the Company shall notify Mr. Mitchell of such term, and such term, at the option of Mr. Mitchell, shall become a part of the Mitchell Note. In addition, Mr. Mitchell received 582 shares of common stock with a value of $3,124; this amount was recorded as a discount to the Mitchell Note. At December 31, 2023, principal and accrued interest in the amount of $78,100 and $15,768, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $78,100 and $18,999, respectively, were due on this note. This note was in default at March 31, 2024. Leath Note On September 15, 2022, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Mack Leath (the “Leath Note”). The Leath Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 15, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Leath Note was $42,500; the amount payable at maturity will be $50,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Leath Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Leath Note entered default status on December 16, 2022, and the interest rate increased to 18%. The Leath Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Leath reasonably believes contains a term that is more favorable than those in the Leath Note, the Company shall notify Mr. Leath of such term, and such term, at the option of Mr. Leath, shall become a part of the Leath Note. In addition, Mr. Leath received 410 shares of common stock with a value of $2,868; this amount was recorded as a discount to the Leath Note. At December 31, 2023, principal and accrued interest in the amount of $55,000 and $10,757, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $55,000 and $13,032, respectively, were due on this note. This note was in default at March 31, 2024. November 29, 2022 Notes On November 29, 2022, the Company issued seven identical promissory notes (the “November 29 Notes”) in related party transactions to the following individuals: (1) Thomas Brodmerkel, who was the Company’s CFO and Board Member; (2) Lawrence Diamond, who was the Company’s Chief Executive Officer and Board Member; (3) Sheila Schweitzer, who was a Board Member; (4) Faraz Naqvi, a former Board Member; (5) Juan Carlos Iturregui, who was a Board Member; (6) Jenny Lindstrom, who was the Company’s former Vice President and Chief Legal Officer; and (7) Michael C. Howe, who was the Chief Executive Officer of The Good Clinic, one of our subsidiaries (collectively, the “November 29 Lenders”). The November 29 notes have due dates of May 28, 2023. The November 29 Notes are subject to the Series E Exchange Agreement whereby each of the November 29 Lenders will exchange (a) amounts due under the November 29 Notes for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of each November 29 Note. See note 13. The November 29 Notes bear interest at the rate of 10% per annum which will accrue from the date of the note only if the November 29 Notes are not converted pursuant to the Series E Exchange Agreement by May 10, 2023. Following an event of default as defined in the November 29 Notes, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The November 29 Notes contain a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which November 29 Lender reasonably believes contains a term that is more favorable than those in the November 29 Note, the Company shall notify the November 29 Lenders of such term, and such term, at the option of the November 29 Lenders, shall become a part of the November 29 Note. In addition, each of the November 29 Lenders will receive five-year warrants to purchase 750 shares of the Company’s common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet determined. Discounts in the amount of $667 were amortized to interest expense for each of the November 29 Notes during the year ended December 31, 2022, and discounts in the amount of $3,083 remained outstanding for each of the November 29 Notes at December 31, 2022. Principal and accrued interest in the amounts $18,750 and $164, respectively, were due on each of the seven November 29 Note at December 31, 2022. Concurrent with the November 29 Notes, the Company entered into separate exchange agreements (the “November 29 Notes Exchange Agreements”). Pursuant to the November 29 Notes Exchange Agreements, amounts due under the November 29 Notes will be exchanged for a number Series E Convertible Preferred Stock equal to 150% of the principal amount of the Notes. No transactions occurred pursuant to the November 29 Notes Exchange Agreements during the year ended December 31, 2022. During the year ended December 31, 2023, interest in the amount of $11,967 was accrued on the November 29 Notes. On September 29, 2023, three of the November 29 Lenders (1) Thomas Brodmerkel, (2) Lawrence Diamond, and (3) Faraz Naqvi converted their November 29 Notes into shares of the Company’s Series F Preferred Stock as follows: Each of the noteholders converted an equity investment incentive in the amount of $13,553 representing 65% of the total amount due under the November 29 Note , along with original principal of $18,750 and accrued interest of $2,101 (a total of $34,404) into 34 shares of the Company’s Series F Preferred Stock. Other than the equity investment incentives of $13,553, there was no gain or loss recognized on this transaction as the Series F Preferred Stock was issued at its face value of $1,000 per share. On September 29, 2023, one of the November 29 Lenders, Sheila Schweitzer, converted her November 29 Note into shares of the Company’s restricted common stock as follows: principal of $18,750 and accrued interest of $2,101 were converted at a price of $0.80 per share into 26,064 shares of the Company’s common stock. On December 8, 2023 pursuant to the Howe debt exchange agreement, Mr. Howe exchanged his note in the principal amount of $18,750 and accrued interest of $2,682 for certain assets of the company. No amounts were due under the Howe note as of December 31, 2023. At December 31, 2023, there was principal and interest in the aggregate amount of $37,500 and $5,903, respectively, due on the two November 29 Notes that are still outstanding. At March 31, 2024, there was principal and interest in the aggregate amount of $37,500 and $6,851, respectively, due on the two November 29 Notes that are still outstanding. Aggregate interest expense as described on the above notes payable – related parties was $10,581 for the three months ended March 31, 2024. Accrued interest on notes payable – related parties was $72,374 and $61,792 at March 31, 2024 and December 31, 2023, respectively.

Derivative Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2024
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	Note 10: Derivative Liabilities Certain of the Company’s convertible notes and warrants contain features that create derivative liabilities. The pricing model the Company uses for determining fair value of its derivatives is the Monte Carlo Model. Valuations derived from this model are subject to ongoing internal and external verification and review. The model uses market-sourced inputs such as interest rates and stock price volatilities. Selection of these inputs involves management’s judgment and may impact net income. The derivative components of these notes are valued at issuance, at conversion, at restructure, and at each period end. Derivative liability activity for the three months ended March 31, 2024 is summarized in the table below: December 31, 2023 $ 152,945 True-up features issued - Settled upon conversion or exercise - Loss on revaluation - March 31, 2024 $ 152,945 The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following tables summarize the assumptions for the valuations: March 31, December 31, 2024 2023 Volatility 475.7 % 95.1% to 123.2 % Stock Price $ 0.0250 $ 1.06 to 3.50 Risk-free interest rates 5.21 % 4.35% to 4.37 % Term (years) 0.39 0.73 to 0.86 Certain of our notes payable contain a commitment fee obligation with a true-up feature. The following assumptions were used for the valuation of the derivative liability associated with this obligation: ● The stock price would fluctuate with the Company projected volatility. ● The projected volatility curve from an annualized analysis for each valuation date was based on the historical volatility of the Company and the term remaining for the True-Up obligation. ● The Company expected the note would be repaid 90% of the time by the maturity date, at which point the Company would redeem the 1,000,000 redeemable commitment fee shares for $1. ● In the event the Company did not repay the note in time, the shareholders would sell their shares subject to volume restrictions. ● Discount rates were based on risk free rates in effect based on the remaining term. 50,000 simulations were run for each Monte Carlo simulation.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	3 Months Ended
	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Equity [Text Block]	Note 11: Stockholders Equity (Deficit) Common Stock The Company has authorized 500,000,000 shares of common stock, par value $0.01; 5,634,027 were issued and outstanding at March 31, 2024. During the three months ended March 31, 2024, the Company issued 66,070 shares of common stock for dividends payable on its Series X Preferred Stock. Preferred Stock We have authorized to issue 100,000,000 shares of Preferred Stock with such rights designations and preferences as determined by our Board of Directors. We have designated 500,000 shares of series A stock, 3,000,000 shares of Series C Preferred, 10,000,000 shares of Series D Preferred, 10,000 shares of Series E Preferred, 140,000 shares of Series F Preferred, and 24,227 shares as Series X Preferred Stock. Series A Preferred Stock The Series A Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share and accrued dividends at the rate of 12% on $25.00 per share. The Company had no shares of Series A Preferred Stock outstanding at March 31, 2024. Series C Preferred Stock The Series C Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of 100% of the stated value plus accrued but unpaid dividends, accrued dividends at the rate of 6% on $1.05 per share, and converts into common shares at a rate of $0.25 per share. The Series C ranks senior to all other preferred stock of the Company except in relation to the Series X Cumulative Redeemable Perpetual Preferred Stock, which ranks Pari passu Series D Preferred Stock The Series D Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of 100% of the stated value plus accrued but unpaid dividends, accrued dividends at the rate of 6% on $1.05 per share, and converts into common shares at a rate of $0.25 per share. The Series D ranks senior to all other preferred stock of the Company except in relation to the Series X Cumulative Redeemable Perpetual Preferred Stock, which ranks Pari passu The Company accrued dividends in the amount of $3,928 on the Series D Preferred Stock for the three months ended March 31, 2024. As of March 31, 2024, the Company had $37,727 in accrued dividends on the Series D Preferred Stock. Series E Preferred Stock On November 7, 2022, the Company filed a Certificate of Designations, Preferences and Rights of Series E Convertible Perpetual Preferred Stock (the “Series E”) with the Delaware Secretary of State. The number of shares of Series E designated is 10,000 and each share of Series E has a stated value equal to $1,000. Each share of Series E Preferred Stock shall have a par value of $0.01. There are 0 shares of Series E Preferred Stock outstanding at March 31, 2024. No shares of Series E Preferred Stock have ever been issued. As long as any shares of Series E are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series E, (a) alter or change the preferences, rights, privileges or powers given to the Series E or alter or amend the Certificate of Incorporation or bylaws, (b) increase or decrease (other than by conversion) the number of authorized shares of Series E, or (c) create or authorize any new class of shares that has a preference over Series E. Unless previously converted into shares of Common Stock, any shares of Series E issued and outstanding, shall be redeemable at the option of the Company for cash at a redemption price per share equal to 110% of the initial issuance price, or $1,100, plus all dividends declared thereon. Each share of Series E shall become convertible, at the option of the holder, commencing on the date of issuance, into such number of fully paid and non-assessable shares of Common Stock. The conversion price shall be, as of the conversion date, (a) prior to the date of the qualified offering the average VWAP per share of the Common Stock for the five (5) trading days prior to the date of conversion and (b) on or following the date of the qualified offering, the qualified offering price (the “Conversion Price”). Immediately following the 120th day following the qualified offering, the Conversion Price shall be adjusted to the lesser of (a) the average VWAP per share of the Common Stock for the five (5) trading days immediately following the 120th day following the qualified offering and (b) the Conversion Price on such date, which shall in no event be less than $0.05. Series F Preferred Stock On March 23, 2023, the Company filed a Certificate of Designations, Preferences and Rights of Series F 12% PIK $0.01 par value Convertible Perpetual Preferred Stock with the Delaware Secretary of State. The number of shares of Series F Preferred Stock designated is 140,000 and each share of Series F Preferred Stock has a liquidation preference of $1,000. The Series F Preferred Stock will rank senior to the Corporation’s Common Stock and on parity with all Preferred Stock of the Corporation with terms specifically providing that such Preferred Stock rank on parity with the Series F Preferred Stock with respect to rights to the distribution of assets upon any liquidation, dissolution or winding up of the Corporation; and (iii) junior to all Preferred Stock of the Corporation with terms specifically providing that such Preferred Stock rank senior to the Series F Preferred Stock with respect to rights to the distribution of assets upon any liquidation, dissolution or winding up of the Company. Holders of shares of the Series F Preferred Stock are entitled to receive payment-in-kind dividends payable only in additional shares of Series F Preferred Stock (“PIK Dividends”) at rate of 12% per annum. The Series F Preferred Stock will be convertible into common stock of the Company upon the listing of the Company’s stock on any of the following trading markets: the NYSE, the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, or the Nasdaq Global Select Market. The conversion price will be calculated as 65% of the volume-weighted average price of the Company’s common stock on the conversion date. The number of shares issuable upon conversion will be calculated as the liquidation preference of the Series F Preferred stock plus any accrued but unpaid dividends divided by the conversion price. There are 20,057 shares of Series F Preferred Stock outstanding at March 31, 2024 The Company accrued dividends in the amount of $608,393 on the Series F Preferred Stock for the three months ended March 31, 2024. As of March 31, 2024, the Company had $2,164,466 in accrued dividends on the Series F Preferred Stock. Series X Preferred Stock The Company has 24,227 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock (the “Series X Preferred Stock”) outstanding as of December 31, 2023 and 2022. The Series X Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company’s common and preferred stock and accrues dividends at the rate of 10% on $25.00 per share. The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. Beginning in July 2023 the Company elected to use a price per share of $.80, a 20% discount to the average price of its common stock of $1.00, before the trading of its common stock was moved to the OTC Expert Market system. Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to a vote of our shareholders. On February 9, 2024, the Company issued 41,057 shares of common stock for dividends payable on its Series X Preferred Stock for the period from July 2023 through December 31, 2023. On March 20, 2024, the Company issued a total of 25,013 shares of restricted common stock for the payment of dividends due for its Series X Preferred stock during the first quarter of 2024 using the $.80 price per share as noted above. The Company accrued dividends in the amount of $26,244 on the Series X Preferred Stock for the three months ended March 31, 2024. As of March 31, 2024, the Company had $0 in accrued dividends on the Series X Preferred Stock. Stock Options On January 21, 2021 the Company filed a Form S-8 containing the Mitesco Omnibus Securities and Incentive Plan (“the Plan”) with the SEC. In Sections 4.2 and 4.3 of the Plan it is noted that the Board of Directors has the authority for administration of the Plan. On January 7, 2024 the Board of Directors voted to a) cancel, revoke and terminate any previously issued options that have not already been exercised. For a number of technical reasons the Plan is no longer valid, and in addition to cancellation of any outstanding options, the Board has voted to formally terminate the Plan. A copy of the Form S-8 which references the Plan can be found at: https://www.sec.gov/Archives/edgar/data/802257/000118518521000098/ex_221520.htm The following table summarizes the options outstanding at March 31, 2024 and the related prices for the options to purchase shares of the Company’s common stock: Weighted Weighted Weighted average average average exercise exercise Range of Number of remaining price of Number of price of exercise options contractual outstanding options exercisable prices outstanding life (years) options exercisable options $ 1.50 13,667 6.04 $ 1.50 13,667 $ 1.50 13,667 6.04 $ 1.50 13,667 $ 1.50 The following table summarizes the transactions involving options to purchase shares of the Company’s common stock: Shares Weighted- Average Exercise Price ($) Outstanding at December 31, 2023 100,934 $ 10.01 Granted - - Cancelled/Expired (87,267 ) $ 11.38 Exercised - - Outstanding at March 31, 2024 13,667 $ 1.50 Options vested and exercisable 13,667 $ 1.50 At March 31, 2024, the total stock-based compensation cost related to unvested awards not yet recognized was $263,422 which vest upon various contingent requirements. At March 31, 2024, there was no intrinsic value on the issued or vested options. Warrants The following table summarizes the warrants outstanding on March 31, 2024, and the related prices for the warrants to purchase shares of the Company’s common stock: Weighted Weighted Weighted average average average exercise exercise Range of Number of remaining price of Number of price of exercise warrants contractual outstanding warrants exercisable prices outstanding life (years) warrants exercisable warrants $ 2.50-37.50 673,208 2.42 $ 30.64 673,208 $ 30.64 673,208 2.42 $ 30.64 673,208 $ 30.64 The following table summarizes the transactions involving options to purchase shares of the Company’s common stock: Shares Weighted- Average Exercise Price ($) Outstanding at December 31, 2023 673,208 $ 30.64 Granted - $ - Exercised - $ - Outstanding at March 31, 2024 673,208 $ 30.64 At March 31, 2024, there was no intrinsic value on the issued or vested options.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 12: Fair Value of Financial Instruments The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at March 31, 2024 and December 31, 2023 . March 31, 2024 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ 152,945 $ 152,945 December 31, 2023 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ 152,945 $ 152,945

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 13: Commitments and Contingencies Legal From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. On June 23, 2022, The Good Clinic LLC was notified that a former employee had filed a lawsuit for wrongful termination. The Good Clinic believes the lawsuit is without merit. Mitesco (Company) was not named in the suit. We have settled this matter as of January 11, 2024 for total consideration consisting of a cash payment of $3,000. On October 25, 2022, the Company was notified that a vendor filed a lawsuit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company’s restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and it issued to the CEO of The Good Clinic 19,622 of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor. The Company has a number of legal situations involved with the winding down of its clinic business activities. These include claims regarding certain construction contracts and cancellation of leases as noted below: Nordhaus Clinic On November 1, 2020, we entered into an agreement to open a clinic in Minneapolis, Minnesota. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $511,000. On November 6, 2023, the Company received a termination notice from the landlord indicating the lease had been terminated. No additional claims have been received by the landlord and the Company believes no additional amounts are owed. Egan Clinic a.k.a. Vikings On October 14, 2021, we entered into an agreement to open a clinic in Eagan, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 96 months. Fixed rent payments under the initial term are approximately $767,000. A Summary Judgment was granted on December 4, 2023, in the amount of $488,491, and the entry of final judgment was entered on December 15, 2023 and the Company has released the property back to the leaseholder. St. Paul Clinic a.k.a. The Grove On August 31, 2021, we entered into an agreement to open a clinic in St. Paul, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 114 months. Fixed rent payments under the initial term are approximately $1,153,000. A stipulation for Judgment was filed on December 21, 2023 in the amount of $415,266. The stipulated judgment includes $178,542 in unpaid back rent, $172,124 in resolution of mechanics’ liens, and $64,600 in attorneys’ fees. Final entry of judgment by the Court was entered against the Company on January 19, 2024, and the Company has released the property back to the leaseholder. St. Louis Park Clinic a.k.a. Excelsior & Grand On May 24, 2021, we entered into an agreement to open a clinic in St. Louis Park, Minnesota, which began operations in the third quarter of 2021. The initial lease term is seven years. Fixed rent payments under the initial term are approximately $673,000. The Company agreed to and executed a Confession of Judgment in the amount of $425,351 on April 2, 2024 and has released the property back to the leaseholder. We received the fully executed and recorded judgement on April 10, 2024. Eden Prairie Clinic a.k.a. TP Elevate On June 8, 2021, we entered into an agreement to open a clinic in Eden Prairie, Minnesota, which began operation in the third quarter of 2021. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $620,000. The Company has surrendered possession of the property and is currently in negotiations the amounts owed and is in the process of settling the remaining amounts owed. Maple Grove Clinic a.k.a. Arbor Lakes On October 8, 2021, we entered into an agreement to open a clinic in Maple Grove, Minnesota which began operation in the fourth quarter of 2021. The initial lease term is for 108 months. Fixed rent payments under the initial term are approximately $1,153,127. On October 22, 2022, the Company entered into a settlement agreement with the leaseholder for $219,576 and the Company has released the property back to the leaseholder. Radiant Clinic a.k.a. LMC Welton On September 9, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 90 months. Fixed rent payments under the initial term are approximately $782,000. As of April 10, 2024, the Company has settled the amounts owed to the leaseholder and full resolution of all liens for approximately $530,000 and the Company has released the property back to the leaseholder. Quincy Clinic a.k.a. 1776 Curtis On September 28, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 94 months. Fixed rent payments under the initial term are approximately $1,079,000. A Final Judgment was granted on November 14, 2023, in the amount of $348,764 including interest, fees and other costs. The Company has released the property back to the leaseholder. The following table summarizes the status of our property settlements as noted above and the total settlement amounts as of the date of the filing: LOCATION ALSO KNOWN AS: PROPERTY NAME/OWNER ORIGINAL OBLIGATION (NOT INC. CAPX) SETTLEMENT AMOUNT TYPE OF SETTLEMENT MINNEAPOLIS, MN NORDHAUS LENNAR $ 511,000 $ - N.A. WAYZETTA, MN PROMINADE WAZETTA BAY $ 407,000 $ 25,000 CASH PAYMENT OBLIGATION EAGAN, MN EAGAN CLINIC VIKINGS $ 767,000 $ 488,491 DEFAULT JUDGEMENT ST. LOUIS PARK, MN EXCELSIOR & GRAND EXCELSIOR $ 673,000 $ 425,350 DEFAULT JUDGEMENT ST. PAUL, MN THE GROVE CONTINENTAL 560 $ 1,153,000 $ 415,606 DEFAULT JUDGEMENT EDEN PRARIE ELEVATE TP ELEVATE $ 620,000 $ - IN PROCESS MAPLE GROVE, MN ARBOR LAKES BUTTNICK $ 1,153,127 $ 219,575 SETTLEMENT AGREE DENVER, CO LMC WELTON RADIANT $ 782,000 $ 530,000 DEFAULT JUDGEMENT DENVER, CO 1776 CURTIS QUINCY $ 1,079,000 $ 348,764 DEFAULT JUDGEMENT TOTAL $ 7,145,127 $ 2,452,768 Administrative offices On June 24, 2021, we entered into an agreement to open an administrative office in St. Louis Park, Minnesota. The initial lease term is 2.5 years. Fixed rent payments under the initial term are approximately $244,000. We have not entered into a settlement agreement on this site as of the date of this filing but expect to shortly.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 14: Subsequent Events Effective April 1, 2024 the Company intends to return to the dividend payment terms as defined in the Certificate of Designation for the Series X Preferred stock, as such the share price used in future dividend payment shall be determined using the closing price of the common stock on the 15 th Advisory Board The Board of Directors recently authorized the creation of a new Advisory Board whose participants shall include subject matter experts in certain business areas under consideration by the Company. These positions are “non-executive” and as such are not governed by Section 16 of the Securities Act. The compensation for the participants shall be $60,000 per year paid through the issuance of restricted common stock. The per share valuation to be used shall be determined by the Board of Directors based on the market of the Company’s common stock at the time of the appointment. On March 19, 2024, the Company announced its first participants to that Board. Each will receive $60,000 of restricted common stock for their services over the next 12 months. The Board has determined that the price per share for the restricted stock shall be $.80, the same pricing used for the payment of dividends to Series X Preferred shareholders. This results in the issuance of 75,000 shares for each member, in aggregate 225,000 shares of restricted common stock. On April 26, 2024 the Board authorized that the per share valuation to be used shall be determined by the Board of Directors based on the market of the Company’s common stock at the time of the appointment. The Board of Director has made April 1, 2024, the effective date for the Advisors appointed through April 1, 2024. On April 26, 2024, the Company announced two additional participants to that Board. Each will receive $60,000 of restricted common stock for their services over the next 12 months. The Board has determined that the price per share for the restricted stock shall be $0.80, resulting in the issuance of 75,000 shares for each member, in aggregate 150,000 shares. On May 10, 2024 the Company issued each of the above four (4) Advisors 75,000 shares of restricted common stock in consideration of their participation on the Advisory Board. The total of 300,000 restricted shares in aggregate were valued at $0.80 each as noted above.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 46,524	$ (5,613,825)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The consolidated financial statements and related disclosures as of March 31, 2024 are unaudited, pursuant to the rules and regulations of the United States Securities and Exchange Commission (“ SEC
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
Earnings Per Share, Policy [Policy Text Block]	Per Share Data -
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations - Presentation of Financial Statements Property, Plant and Equipment
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Standards ASU 2023-07 Segment Reporting ( Topic 280 Improvements to Reportable Segment Disclosures, In December 2023, the FASB issued ASU 2023-09 Income Taxes ( Topic 740 Improvements to Income Tax Disclosures, There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations [Table Text Block]	The following information presents the major classes of line items constituting the after-tax loss from discontinued operations in the consolidated statements of operations: Three Months Ended March 31, March 31, 2024 2023 Revenue $ - $ - Cost of goods sold - 2,419 Gross margin - (2,419 ) Selling, general, and administrative expenses - (381,501 ) Impairment of assets - (2,143,428 ) Other (income) expense: Gain on termination of operating lease - 287,897 Interest expense - (85,593 ) Loss from discontinued operations, net of tax $ - $ (2,325,044 ) Three Months Ended March 31, March 31, 2024 2023 Depreciation expense $ - $ 33,262 Impairment of property and equipment $ - $ 2,271,893 Changes in accounts payable and accrued liabilities $ - $ 549,929

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued liabilities consisted of the following at March 31, 2024 and December 31, 2023: March 31, December 31, 2024 2023 Trade accounts payable $ 6,604,738 $ 7,094,334 Accrued payroll and payroll taxes 788,496 743,778 Total accounts payable and accrued liabilities $ 7,393,234 $ 7,838,112

Right to Use Assets and Lease_2

Right to Use Assets and Lease Liabilities – Operating Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Disclosure Text Block [Abstract]
Lease, Cost [Table Text Block]	Operating lease liabilities are summarized below: March 31, 2024 December 31, 2023 Lease liability $ 99,477 $ 99,477 Less: current portion (99,477 ) (99,477 ) Lease liability, non-current $ - $ -
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	For all leases for which a legal settlement have been entered into, all amounts have been reclassified to legal settlements as of March 31, 2024 and December 31, 2023. For the period ended December 31, 2024 $ 99,477 For the period ended December 31, 2025 - For the period ended December 31, 2026 - For the period ended December 31, 2027 - For the period ended December 31, 2028 - Thereafter - Total $ 99,477 Less: Present value discount - Lease liability $ 99,477

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Payable (Tables) [Line Items]
Schedule of Debt [Table Text Block]	The following table summarizes the outstanding notes payable as of March 31, 2024 and December 31, 2023, respectively: March 31, 2024 December 31, 2023 Kishon Note $ 431,666 $ 431,666 Finnegan Note 1 51,765 51,765 Finnegan Note 2 32,353 32,353 Schrier Note 25,882 25,882 Nommsen Note 64,705 64,705 Caplan Note 64,705 64,705 Finnegan Note 3 32,353 32,353 Lightmas Note 66,000 66,000 Lewis Note 33,000 33,000 Goff Note 33,000 33,000 Hagan Note 110,000 110,000 Cavalry Note 1 25,000 - Cavalry Note 2 50,000 - Mercer Note 1 25,000 - Mercer Note 2 50,000 - ABJ Note 50,000 - Notes Payable $ 1,142,429 $ 945,429 Current Portion $ 1,145,429 $ 945,429 Long-term portion $ - $ -
Related Party [Member]
Notes Payable (Tables) [Line Items]
Schedule of Debt [Table Text Block]	The following table summarizes the outstanding related party notes payable as of March 31, 2024 and December 31, 2023, respectively March 31, 2024 December 31, 2023 M Diamond Note 64,706 64,706 Dobbertin Note 19,412 19,412 Lindstrom Note 45,294 45,294 Mitchell Note 78,100 78,100 Leath Note 55,000 55,000 November 29, 2022 Notes 37,500 37,500 Notes Payable 300,012 300,012 Current Portion, net of discount $ 300,012 $ 300,012 Long-term portion, net of discount $ - $ -

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Disclosure Text Block [Abstract]
Schedule of Derivative Instruments [Table Text Block]	Derivative liability activity for the three months ended March 31, 2024 is summarized in the table below: December 31, 2023 $ 152,945 True-up features issued - Settled upon conversion or exercise - Loss on revaluation - March 31, 2024 $ 152,945
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]	The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following tables summarize the assumptions for the valuations: March 31, December 31, 2024 2023 Volatility 475.7 % 95.1% to 123.2 % Stock Price $ 0.0250 $ 1.06 to 3.50 Risk-free interest rates 5.21 % 4.35% to 4.37 % Term (years) 0.39 0.73 to 0.86

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	3 Months Ended
	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	The following table summarizes the options outstanding at March 31, 2024 and the related prices for the options to purchase shares of the Company’s common stock: Weighted Weighted Weighted average average average exercise exercise Range of Number of remaining price of Number of price of exercise options contractual outstanding options exercisable prices outstanding life (years) options exercisable options $ 1.50 13,667 6.04 $ 1.50 13,667 $ 1.50 13,667 6.04 $ 1.50 13,667 $ 1.50
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	The following table summarizes the transactions involving options to purchase shares of the Company’s common stock: Shares Weighted- Average Exercise Price ($) Outstanding at December 31, 2023 100,934 $ 10.01 Granted - - Cancelled/Expired (87,267 ) $ 11.38 Exercised - - Outstanding at March 31, 2024 13,667 $ 1.50 Options vested and exercisable 13,667 $ 1.50
Schedule Of Warrant Purchase Exercise Price Range [Table Text Block]	The following table summarizes the warrants outstanding on March 31, 2024, and the related prices for the warrants to purchase shares of the Company’s common stock: Weighted Weighted Weighted average average average exercise exercise Range of Number of remaining price of Number of price of exercise warrants contractual outstanding warrants exercisable prices outstanding life (years) warrants exercisable warrants $ 2.50-37.50 673,208 2.42 $ 30.64 673,208 $ 30.64 673,208 2.42 $ 30.64 673,208 $ 30.64
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table summarizes the transactions involving options to purchase shares of the Company’s common stock: Shares Weighted- Average Exercise Price ($) Outstanding at December 31, 2023 673,208 $ 30.64 Granted - $ - Exercised - $ - Outstanding at March 31, 2024 673,208 $ 30.64

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at March 31, 2024 and December 31, 2023 . March 31, 2024 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ 152,945 $ 152,945 December 31, 2023 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ 152,945 $ 152,945

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Property Settlement Obligations [Table Text Block]	The following table summarizes the status of our property settlements as noted above and the total settlement amounts as of the date of the filing: LOCATION ALSO KNOWN AS: PROPERTY NAME/OWNER ORIGINAL OBLIGATION (NOT INC. CAPX) SETTLEMENT AMOUNT TYPE OF SETTLEMENT MINNEAPOLIS, MN NORDHAUS LENNAR $ 511,000 $ - N.A. WAYZETTA, MN PROMINADE WAZETTA BAY $ 407,000 $ 25,000 CASH PAYMENT OBLIGATION EAGAN, MN EAGAN CLINIC VIKINGS $ 767,000 $ 488,491 DEFAULT JUDGEMENT ST. LOUIS PARK, MN EXCELSIOR & GRAND EXCELSIOR $ 673,000 $ 425,350 DEFAULT JUDGEMENT ST. PAUL, MN THE GROVE CONTINENTAL 560 $ 1,153,000 $ 415,606 DEFAULT JUDGEMENT EDEN PRARIE ELEVATE TP ELEVATE $ 620,000 $ - IN PROCESS MAPLE GROVE, MN ARBOR LAKES BUTTNICK $ 1,153,127 $ 219,575 SETTLEMENT AGREE DENVER, CO LMC WELTON RADIANT $ 782,000 $ 530,000 DEFAULT JUDGEMENT DENVER, CO 1776 CURTIS QUINCY $ 1,079,000 $ 348,764 DEFAULT JUDGEMENT TOTAL $ 7,145,127 $ 2,452,768

Going Concern (Details)

Going Concern (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 40,785	$ 2,838
Liabilities, Current	$ 14,726,727	$ 14,134,595

Discontinued Operations (Detail

Discontinued Operations (Details) $ in Millions	Dec. 08, 2023 USD ($)
Discontinued Operations and Disposal Groups [Abstract]
Proceeds from Sale of Productive Assets	$ 2.5

Discontinued Operations (Deta_2

Discontinued Operations (Details) - Disposal Groups, Including Discontinued Operations - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disposal Groups Including Discontinued Operations Abstract
Revenue	$ 0	$ 0
Cost of goods sold	0	2,419
Gross margin	0	(2,419)
Selling, general, and administrative expenses	0	(381,501)
Impairment of assets	0	(2,143,428)
Gain on termination of operating lease	0	287,897
Interest expense	0	(85,593)
Loss from discontinued operations, net of tax	0	(2,325,044)
Depreciation expense	0	33,262
Impairment of property and equipment	0	2,271,893
Changes in accounts payable and accrued liabilities	$ 0	$ 549,929

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule Of Accounts Payable And Accrued Liabilities Abstract
Trade accounts payable	$ 6,604,738	$ 7,094,334
Accrued payroll and payroll taxes	788,496	743,778
Total accounts payable and accrued liabilities	$ 7,393,234	$ 7,838,112

Right to Use Assets and Lease_3

Right to Use Assets and Lease Liabilities – Operating Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Disclosure Text Block [Abstract]
Estimated Litigation Liability, Current	$ 2,452,768	$ 2,219,886
Gain (Loss) Related to Litigation Settlement	$ 233,205

Right to Use Assets and Lease_4

Right to Use Assets and Lease Liabilities – Operating Leases (Details) - Lease, Cost - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Lease, Cost [Abstract]
Lease liability	$ 99,477	$ 99,477
Less: current portion	(99,477)	(99,477)
Lease liability, non-current	$ 0	$ 0

Right to Use Assets and Lease_5

Right to Use Assets and Lease Liabilities – Operating Leases (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 15, 2023	Nov. 14, 2023	Oct. 14, 2021	Oct. 08, 2021	Sep. 28, 2021	Sep. 21, 2021	Jun. 08, 2021	May 04, 2021	Nov. 01, 2020
Lessee Operating Lease Liability Maturity Abstract
For the period ended December 31, 2024	$ 99,477
For the period ended December 31, 2025	0
For the period ended December 31, 2026	0
For the period ended December 31, 2027	0
For the period ended December 31, 2028	0
Thereafter	0
Total	99,477		$ 1,153,000	$ 244,000	$ 767,000	$ 1,153,127	$ 1,079,000	$ 782,000	$ 620,000	$ 673,000	$ 511,000
Less: Present value discount	0
Lease liability	$ 99,477	$ 99,477

SBA Loan Payable (Details)

SBA Loan Payable (Details) - USD ($)		3 Months Ended	12 Months Ended
	Jul. 12, 2023	Mar. 31, 2024	Dec. 31, 2023	May 04, 2020
SBA Loan Payable (Details) [Line Items]
Debt Instrument, Periodic Payment	$ 2,595
Loans Payable to Bank	$ 467,117
Notes Payable		$ 1,142,429	$ 945,429
PPP Loan [Member]
SBA Loan Payable (Details) [Line Items]
Debt Instrument, Face Amount				$ 460,400
Debt Instrument, Interest Rate, Effective Percentage			1%	1%
Gains (Losses) on Restructuring of Debt			$ 40,622
Notes Payable			$ 433,343
Repayments of Debt		7,786
PPP Loan [Member] | Accrued Interest [Member]
SBA Loan Payable (Details) [Line Items]
Repayments of Debt		$ 1,052

Notes Payable (Details)

Notes Payable (Details) - USD ($)

3 Months Ended

12 Months Ended

Feb. 28, 2024

Jan. 23, 2024

Dec. 08, 2023

Sep. 29, 2023

Nov. 29, 2022

Sep. 15, 2022

Sep. 02, 2022

Aug. 04, 2022

Jul. 27, 2022

Jul. 26, 2022

Jul. 07, 2022

Jun. 09, 2022

May 26, 2022

May 23, 2022

May 10, 2022

Dec. 30, 2021

Mar. 31, 2024

Mar. 31, 2023

Dec. 31, 2023

Dec. 31, 2022

Notes Payable (Details) [Line Items]

Class of Warrant or Rights, Granted (in Shares)

0

Derivative Liability, Current

$ 152,945

$ 152,945

Proceeds from Issuance of Debt

$ 200,000

$ 0

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 30.64

$ 30.64

Warrants and Rights Outstanding

$ 673,208

Interest Expense, Debt

$ 40,624

Minimum [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 2.5

Kishon Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 159,259

Stock Issued During Period, Shares, Other (in Shares)

12,741

Class of Warrant or Rights, Granted (in Shares)

5,556

Derivative Liability, Current

$ 27,793

Debt Instrument, Face Amount

277,777

Proceeds from Issuance of Debt

250,000

Debt Instrument, Unamortized Discount

$ 138,492

Debt Instrument, Maturity Date

Nov. 10, 2022

Debt Instrument, Interest Rate, Stated Percentage

12%

Debt Instrument, Fee Amount

$ 15,000

Debt Instrument, Debt Default, Amount

$ 431,666

431,666

Interest Payable

108,281

88,909

Kishon Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Kishon Note [Member] | Minimum [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

10%

Finnegan Note 1 [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 3,240

Stock Issued During Period, Shares, Other (in Shares)

1,930

Debt Instrument, Face Amount

$ 47,059

Proceeds from Issuance of Debt

$ 40,000

Debt Instrument, Maturity Date

Nov. 20, 2022

Debt Instrument, Debt Default, Amount

51,765

51,765

Interest Payable

14,030

11,889

Warrants and Rights Outstanding

$ 2,000

Finnegan Note 1 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Finnegan Note 1 [Member] | Warrants at $25.00 [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Rights, Granted (in Shares)

386

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Finnegan Note 2 [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 2,025

Stock Issued During Period, Shares, Other (in Shares)

242

Debt Instrument, Face Amount

$ 29,412

Proceeds from Issuance of Debt

$ 25,000

Debt Instrument, Maturity Date

Nov. 30, 2022

Debt Instrument, Debt Default, Amount

32,353

32,353

Interest Payable

8,679

7,341

Warrants and Rights Outstanding

$ 1,250

Finnegan Note 2 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Finnegan Note 2 [Member] | Warrants at $25.00 [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Rights, Granted (in Shares)

242

Share Price (in Dollars per share)

$ 25

Schrier Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 1,000

Stock Issued During Period, Shares, Other (in Shares)

193

Class of Warrant or Rights, Granted (in Shares)

193

Debt Instrument, Face Amount

$ 23,259

Proceeds from Issuance of Debt

$ 20,000

Debt Instrument, Maturity Date

Jan. 08, 2023

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

25,882

25,882

Interest Payable

6,454

5,383

Warrants and Rights Outstanding

$ 820

Schrier Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Schrier Note [Member] | Warrants at $25.00 [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Nommsen Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 2,350

Stock Issued During Period, Shares, Other (in Shares)

483

Debt Instrument, Face Amount

$ 58,823

Proceeds from Issuance of Debt

$ 50,000

Debt Instrument, Maturity Date

Nov. 30, 2022

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

64,705

64,705

Interest Payable

16,361

13,685

Warrants and Rights Outstanding

$ 1,850

Nommsen Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Nommsen Note [Member] | Warrants at $25.00 [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Rights, Granted (in Shares)

483

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Caplan Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 2,350

Stock Issued During Period, Shares, Other (in Shares)

483

Debt Instrument, Face Amount

$ 58,823

Proceeds from Issuance of Debt

$ 50,000

Debt Instrument, Maturity Date

Jan. 21, 2023

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

64,705

64,705

Interest Payable

15,665

12,989

Warrants and Rights Outstanding

$ 1,850

Caplan Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Caplan Note [Member] | Warrants at $25.00 [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Rights, Granted (in Shares)

483

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Finnegan Note 3 [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 1,100

Stock Issued During Period, Shares, Other (in Shares)

242

Debt Instrument, Face Amount

$ 29,412

Proceeds from Issuance of Debt

$ 25,000

Debt Instrument, Maturity Date

Feb. 03, 2023

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

32,353

32,353

Interest Payable

7,688

6,350

Warrants and Rights Outstanding

$ 850

Finnegan Note 3 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Finnegan Note 3 [Member] | Warrants at $25.00 [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Rights, Granted (in Shares)

242

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Lightmas Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 2,640

Stock Issued During Period, Shares, Other (in Shares)

492

Debt Instrument, Face Amount

$ 60,000

Proceeds from Issuance of Debt

$ 51,000

Debt Instrument, Maturity Date

Nov. 30, 2022

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

66,000

66,000

Interest Payable

16,055

13,325

Lightmas Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Lewis Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 1,320

Stock Issued During Period, Shares, Other (in Shares)

246

Debt Instrument, Face Amount

$ 30,000

Proceeds from Issuance of Debt

$ 25,500

Debt Instrument, Maturity Date

Nov. 30, 2022

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

33,000

33,000

Interest Payable

8,028

6,663

Lewis Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Goff Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 1,320

Stock Issued During Period, Shares, Other (in Shares)

246

Debt Instrument, Face Amount

$ 30,000

Proceeds from Issuance of Debt

$ 25,500

Debt Instrument, Maturity Date

Nov. 30, 2022

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

33,000

33,000

Interest Payable

8,028

6,663

Goff Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Hagan Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 4,715

Stock Issued During Period, Shares, Other (in Shares)

820

Debt Instrument, Face Amount

$ 100,000

Proceeds from Issuance of Debt

$ 85,000

Debt Instrument, Maturity Date

Dec. 10, 2022

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

110,000

110,000

Interest Payable

26,343

21,793

Hagan Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Cavalry Note 1 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 25,000

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

25,000

Interest Payable

465

Cavalry Note 1 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

12%

Cavalry Note 2 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 50,000

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

50,000

Interest Payable

431

Cavalry Note 2 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

12%

Mercer Note 1 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 25,000

Debt Instrument, Maturity Date

Jan. 23, 2025

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

25,000

Interest Payable

465

Mercer Note 1 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

12%

Mercer Note 2 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 50,000

Debt Instrument, Maturity Date

Feb. 28, 2025

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

50,000

Debt Instrument, Increase, Accrued Interest

431

Mercer Note 2 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

12%

AJB Capital Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 50,000

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

50,000

Interest Payable

431

Notes Payable, Other Payables [Member]

Notes Payable (Details) [Line Items]

Interest Payable, Current

389,444

348,821

M Diamond Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 4,050

Stock Issued During Period, Shares, Other (in Shares)

483

Debt Instrument, Face Amount

$ 58,823

Proceeds from Issuance of Debt

$ 50,000

Debt Instrument, Maturity Date

Nov. 30, 2022

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

64,706

64,706

Interest Payable

16,169

14,682

Warrants and Rights Outstanding

$ 2,500

M Diamond Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

M Diamond Note [Member] | Warrants at $25.00 [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Rights, Granted (in Shares)

483

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Dobbertin Note 1 [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 1,215

Stock Issued During Period, Shares, Other (in Shares)

145

Class of Warrant or Rights, Granted (in Shares)

145

Debt Instrument, Face Amount

$ 17,647

Proceeds from Issuance of Debt

$ 15,000

Debt Instrument, Maturity Date

Nov. 30, 2022

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

19,412

19,412

Interest Payable

5,197

4,405

Warrants and Rights Outstanding

$ 750

Dobbertin Note 1 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Dobbertin Note 1 [Member] | Warrants at $25.00 [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Lindstrom Note 1 [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 2,835

Stock Issued During Period, Shares, Other (in Shares)

338

Class of Warrant or Rights, Granted (in Shares)

338

Debt Instrument, Face Amount

$ 41,176

Proceeds from Issuance of Debt

$ 35,000

Debt Instrument, Maturity Date

Nov. 30, 2022

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

45,294

45,294

Interest Payable

12,125

10,277

Warrants and Rights Outstanding

$ 1,750

Lindstrom Note 1 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Lindstrom Note 1 [Member] | Warrants at $25.00 [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Mitchell Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 71,000

Proceeds from Issuance of Debt

$ 60,350

Debt Instrument, Maturity Date

Nov. 30, 2022

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

78,100

78,100

Interest Payable

18,999

15,768

Mitchell Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Leath Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 2,868

Stock Issued During Period, Shares, Other (in Shares)

410

Debt Instrument, Face Amount

$ 50,000

Proceeds from Issuance of Debt

$ 42,500

Debt Instrument, Maturity Date

Dec. 15, 2022

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Debt Default, Amount

55,000

55,000

Interest Payable

13,032

10,757

Leath Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

November 29, 2022 Notes [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Rights, Granted (in Shares)

750

Debt Instrument, Unamortized Discount

$ 3,083

Debt Instrument, Maturity Date

May 28, 2023

Debt Instrument, Debt Default, Amount

37,500

37,500

18,750

Interest Payable

6,851

5,903

164

Debt Instrument, Increase, Accrued Interest

11,967

Amortization of Debt Discount (Premium)

$ 667

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

26,064

Debt Related Commitment Fees and Debt Issuance Costs

$ 13,553

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 0.8

November 29, 2022 Notes [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

November 29, 2022 Notes [Member] | Investment Incentive [Member]

Notes Payable (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 13,553

November 29, 2022 Notes [Member] | Convertible Notes Payable [Member]

Notes Payable (Details) [Line Items]

Debt Conversion, Original Debt, Amount

18,750

November 29, 2022 Notes [Member] | Accrued Interest [Member]

Notes Payable (Details) [Line Items]

Debt Conversion, Original Debt, Amount

2,101

Howe Note [Member] | Convertible Notes Payable [Member]

Notes Payable (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 18,750

Howe Note [Member] | Accrued Interest [Member]

Notes Payable (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 2,682

Warrants at $25.00 [Member] | Mitchell Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 3,124

Stock Issued During Period, Shares, Other (in Shares)

582

Series F Preferred Stock [Member] | November 29, 2022 Notes [Member]

Notes Payable (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 34,404

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

34

Series F Preferred Stock [Member] | November 29, 2022 Notes [Member] | Convertible Notes Payable [Member]

Notes Payable (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 18,750

Series F Preferred Stock [Member] | November 29, 2022 Notes [Member] | Accrued Interest [Member]

Notes Payable (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 2,101

Original Issue Discount [Member] | Kishon Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Unamortized Discount

$ 27,777

Default Penalty [Member] | Kishon Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Fee Amount

138,889

Related Party [Member]

Notes Payable (Details) [Line Items]

Interest Payable

72,374

61,792

Interest Expense, Debt

10,581

Interest Payable, Current

72,374

$ 61,792

Amortization of Debt Discount (Premium)

$ 0

$ 11,131

Notes Payable (Details) - Sche

Notes Payable (Details) - Schedule of Debt - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes payable - net of discount	$ 1,142,429	$ 945,429
Current Portion, net of discount	1,145,429	945,429
Long-term portion, net of discount	0	0
Kishon Note [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	431,666	431,666
Finnegan Note 1 [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	51,765	51,765
Finnegan Note 2 [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	32,353	32,353
Schrier Note [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	25,882	25,882
Nommsen Note [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	64,705	64,705
Caplan Note [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	64,705	64,705
Finnegan Note 3 [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	32,353	32,353
Lightmas Note [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	66,000	66,000
Lewis Note [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	33,000	33,000
Goff Note [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	33,000	33,000
Hagan Note [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	110,000	110,000
Cavalry Note 1 [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	25,000	0
Cavalry Note 2 [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	50,000	0
Mercer Note [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	25,000	0
Cavalry Note 3 [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	50,000	0
AJB Capital Note [Member]
Notes Payable (Details) - Schedule of Debt [Line Items]
Notes Payable	$ 50,000	$ 0

Notes Payable _ Related Parties

Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties - Related Party [Member] - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]
Notes payable – net of discounts	$ 300,012	$ 300,012
Current Portion, net of discount	300,012	300,012
Long-term portion, net of discount	0	0
M Diamond Note [Member]
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]
Notes Payable	64,706	64,706
Dobbertin Note 1 [Member]
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]
Notes Payable	19,412	19,412
Lindstrom Note 1 [Member]
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]
Notes Payable	45,294	45,294
Mitchell Note [Member]
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]
Notes Payable	78,100	78,100
Leath Note [Member]
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]
Notes Payable	55,000	55,000
November 29, 2022 Notes [Member]
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]
Notes Payable	$ 37,500	$ 37,500

Derivative Liabilities (Details

Derivative Liabilities (Details) - Schedule of Derivative Liability Acitivity	3 Months Ended
	Mar. 31, 2024 USD ($)
Schedule Of Derivative Liability Acitivity Abstract
Balance	$ 152,945
True-up features issued	0
Settled upon conversion or exercise	0
Loss on revaluation	0
Balance	$ 152,945

Derivative Liabilities (Detai_2

Derivative Liabilities (Details) - Schedule of Valuation Assumptions - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Derivative Liabilities (Details) - Schedule of Valuation Assumptions [Line Items]
Volatility	475.70%
Stock Price (in Dollars per share)	$ 0.025
Risk-free interest rates	5.21%
Term (years)	4 months 20 days
Minimum [Member]
Derivative Liabilities (Details) - Schedule of Valuation Assumptions [Line Items]
Volatility		95.10%
Stock Price (in Dollars per share)		$ 1.06
Risk-free interest rates		4.35%
Term (years)		8 months 23 days
Maximum [Member]
Derivative Liabilities (Details) - Schedule of Valuation Assumptions [Line Items]
Volatility		123.20%
Stock Price (in Dollars per share)		$ 3.5
Risk-free interest rates		4.37%
Term (years)		10 months 9 days

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details) - USD ($)					3 Months Ended
	Mar. 20, 2024	Feb. 09, 2024	Jul. 01, 2023	Nov. 07, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Mar. 23, 2023
Stockholders' Equity (Deficit) (Details) [Line Items]
Common Stock, Shares Authorized					500,000,000		500,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)					$ 0.01		$ 0.01
Common Stock, Shares, Issued					5,634,027		5,567,957
Common Stock, Shares, Outstanding					5,634,027		5,567,957
Common Stock Dividends, Shares					66,070
Preferred Stock, Shares Authorized					100,000,000
Dividends, Preferred Stock (in Dollars)					$ 638,565	$ 79,818
Series A Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Preferred Stock, Shares Authorized					500,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)					$ 0.01		$ 0.01
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)					$ 25
Preferred Stock, Dividend Rate, Percentage					12%
Preferred Stock, Dividend Rate, Per-Dollar-Amount (in Dollars per share)					$ 25
Preferred Stock, Shares Outstanding					0		0
Series C Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Preferred Stock, Shares Authorized					3,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)					$ 0.01		$ 0.01
Preferred Stock, Dividend Rate, Percentage					6%
Preferred Stock, Dividend Rate, Per-Dollar-Amount (in Dollars per share)					$ 1.05
Preferred Stock, Shares Outstanding					0		0
Preferred Stock, Convertible, Conversion Price (in Dollars per share)					$ 0.25
Series D Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Preferred Stock, Shares Authorized					10,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)					$ 0.01		$ 0.01
Preferred Stock, Dividend Rate, Percentage					6%
Preferred Stock, Dividend Rate, Per-Dollar-Amount (in Dollars per share)					$ 1.05
Preferred Stock, Shares Outstanding					250,000		250,000
Common Stock, Convertible, Conversion Price, Increase (in Dollars per share)					$ 0.25
Dividends, Preferred Stock (in Dollars)					$ 3,928
Preferred Stock, Amount of Preferred Dividends in Arrears (in Dollars)					$ 37,727
Series E Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Preferred Stock, Shares Authorized					10,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)				$ 0.01
Preferred Stock, Shares Outstanding					0
Preferred Stock, Convertible, Conversion Price (in Dollars per share)				$ 0.05
Stock Issued During Period, Shares, New Issues				10,000
Stock Issued During Period, Value, New Issues (in Dollars)				$ 1,000
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars)				$ 1,100
Series F Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Preferred Stock, Shares Authorized					140,000			140,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)					$ 0.01		$ 0.01	$ 0.01
Preferred Stock, Shares Outstanding					20,057		20,057
Dividends, Preferred Stock (in Dollars)					$ 608,393
Preferred Stock, Amount of Preferred Dividends in Arrears (in Dollars)					$ 2,164,466
Preferred Stock, Value, Outstanding (in Dollars)								$ 1,000
Series X Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Common Stock Dividends, Shares	25,013	41,057
Preferred Stock, Shares Authorized					24,227
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)					$ 0.01		$ 0.01
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)					$ 25
Preferred Stock, Shares Outstanding					24,227		24,227
Dividends, Preferred Stock (in Dollars)					$ 26,244
Preferred Stock, Amount of Preferred Dividends in Arrears (in Dollars)					$ 0
Preferred Stock, Dividend Payment Terms					The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration.
Share Price (in Dollars per share)			$ 0.80
Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date			20%
Preferred Stock, Voting Rights					Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to a vote of our shareholders.
Common Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Share Price (in Dollars per share)			$ 1
Two Service Providers [Member] | Series F Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)	$ 0.80
Share-Based Payment Arrangement, Option [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars)					$ 263,422

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) (Details) - Share-Based Payment Arrangement, Option, Exercise Price Range - $ / shares	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share Based Payment Arrangement Option Exercise Price Range Abstract
Range of exercise prices	$ 1.5
Number of options outstanding (in Shares) (in Shares)	13,667	100,934
Weighted average remaining contractual life (years)	6 years 14 days
Weighted average exercise price of outstanding options	$ 1.5	$ 10.01
Number of options exercisable (in Shares) (in Shares)	13,667
Weighted average exercise price of exercisable options	$ 1.5

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) (Details) - Share-Based Payment Arrangement, Option, Activity	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share Based Payment Arrangement Option Activity Abstract
Outstanding, Number of Shares | shares	100,934
Outstanding, Weighted-Average Exercise Price | $ / shares	$ 10.01
Options Vested and Exercisable, Number of Shares | shares	13,667
Options Vested and Exercisable, Weighted-Average Exercise Price | $ / shares	$ 1.5
Granted, Number of Shares | shares	0
Granted, Weighted-Average Exercise Price | $ / shares	$ 0
Cancelled/Expired, Number of Shares | shares	(87,267)
Cancelled/Expired, Weighted-Average Exercise Price | $ / shares	$ 11.38
Exercised, Number of Shares | shares	0
Exercised, Weighted-Average Exercise Price | $ / shares	$ 0
Outstanding, Number of Shares | shares	13,667
Outstanding, Weighted-Average Exercise Price | $ / shares	$ 1.5

Stockholders' Equity (Deficit_5

Stockholders' Equity (Deficit) (Details) - Schedule Of Warrants Purchase Exercise Price Range - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Stockholders' Equity (Deficit) (Details) - Schedule Of Warrants Purchase Exercise Price Range [Line Items]
Range of exercise prices	$ 30.64	$ 30.64
Number of warrants outstanding (in Dollars)	$ 673,208
Weighted average remaining contractual life (years)	2 years 5 months 1 day
Weighted average exercise price of outstanding warrants	$ 30.64	30.64
Number of warrants exercisable (in Shares)	673,208
Weighted average exercise price of exercisable warrants	$ 30.64	$ 30.64
Minimum [Member]
Stockholders' Equity (Deficit) (Details) - Schedule Of Warrants Purchase Exercise Price Range [Line Items]
Range of exercise prices	2.5
Weighted average exercise price of outstanding warrants	2.5
Weighted average exercise price of exercisable warrants	2.5
Maximum [Member]
Stockholders' Equity (Deficit) (Details) - Schedule Of Warrants Purchase Exercise Price Range [Line Items]
Range of exercise prices	37.5
Weighted average exercise price of outstanding warrants	37.5
Weighted average exercise price of exercisable warrants	$ 37.5

Stockholders' Equity (Deficit_6

Stockholders' Equity (Deficit) (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Schedule Of Stockholders Equity Note Warrants Or Rights Abstract
Outstanding, Number of Shares | shares	673,208
Outstanding, Weighted Average Exercise Price | $ / shares	$ 30.64
Granted, Number of Shares | shares	0
Granted, Weighted Average Exercise Price | $ / shares	$ 0
Exercised, Number of Shares | shares	0
Exercised, Weighted Average Exercise Price | $ / shares	$ 0
Outstanding, Number of Shares | shares	673,208
Outstanding, Weighted Average Exercise Price | $ / shares	$ 30.64

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]
Derivative liabilities	$ 152,945	$ 152,945
Fair Value, Inputs, Level 1 [Member]
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]
Derivative liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]
Derivative liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]
Derivative liabilities	$ 152,945	$ 152,945

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)

Apr. 10, 2024

Apr. 02, 2024

Jan. 11, 2024

Dec. 21, 2023

Dec. 15, 2023

Nov. 14, 2023

Oct. 25, 2022

Oct. 22, 2022

Mar. 31, 2024

Oct. 14, 2021

Oct. 08, 2021

Sep. 28, 2021

Sep. 21, 2021

Jun. 08, 2021

May 04, 2021

Nov. 01, 2020

Commitments and Contingencies (Details) [Line Items]

Litigation Settlement, Expense

$ 3,000

$ 3,000

Lessee, Operating Lease, Term of Contract

114 months

2 years 6 months

96 months

108 months

94 months

90 months

8 years

7 years

8 years

Lessee, Operating Lease, Liability, to be Paid

$ 1,153,000

$ 244,000

$ 99,477

$ 767,000

$ 1,153,127

$ 1,079,000

$ 782,000

$ 620,000

$ 673,000

$ 511,000

Settled Litigation [Member]

Commitments and Contingencies (Details) [Line Items]

Litigation Settlement, Amount Awarded to Other Party

$ 530,000

Judicial Ruling [Member]

Commitments and Contingencies (Details) [Line Items]

Litigation Settlement, Amount Awarded to Other Party

$ 425,351

$ 488,491

$ 348,764

$ 219,576

Loss Contingency, Actions Taken by Plaintiff

A stipulation for Judgment was filed on December 21, 2023 in the amount of $415,266. The stipulated judgment includes $178,542 in unpaid back rent, $172,124 in resolution of mechanics’ liens, and $64,600 in attorneys’ fees.

Restricted Stock [Member] | Settled Litigation [Member]

Commitments and Contingencies (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares)

2,552

Restricted Stock [Member] | CEO of The Good Clinic [Member] | Settled Litigation [Member]

Commitments and Contingencies (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares)

19,622

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
ORIGINAL OBLIGATION	$ 7,145,127
SETTLEMENT AMOUNT	96,136	$ 121,136
Settled Litigation [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
SETTLEMENT AMOUNT	2,452,768
Nordhaus Minneapolis, MN [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
ORIGINAL OBLIGATION	511,000
Nordhaus Minneapolis, MN [Member] | Settled Litigation [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
SETTLEMENT AMOUNT	0
Prominade Wayzetta, MN [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
ORIGINAL OBLIGATION	407,000
Prominade Wayzetta, MN [Member] | Settled Litigation [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
SETTLEMENT AMOUNT	25,000
Eagan Clinic Eagan, MN [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
ORIGINAL OBLIGATION	767,000
Eagan Clinic Eagan, MN [Member] | Settled Litigation [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
SETTLEMENT AMOUNT	488,491
Excelsior & Grand St. Louis Park, MN [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
ORIGINAL OBLIGATION	673,000
Excelsior & Grand St. Louis Park, MN [Member] | Settled Litigation [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
SETTLEMENT AMOUNT	425,350
The Grove St. Paul, MN [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
ORIGINAL OBLIGATION	1,153,000
The Grove St. Paul, MN [Member] | Settled Litigation [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
SETTLEMENT AMOUNT	415,606
Elevate Eden Prarie [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
ORIGINAL OBLIGATION	620,000
Elevate Eden Prarie [Member] | Settled Litigation [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
SETTLEMENT AMOUNT	0
Arbor Lakes Maple Grave, MN [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
ORIGINAL OBLIGATION	1,153,127
Arbor Lakes Maple Grave, MN [Member] | Settled Litigation [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
SETTLEMENT AMOUNT	219,575
LMC Welton Denver, CO [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
ORIGINAL OBLIGATION	782,000
LMC Welton Denver, CO [Member] | Settled Litigation [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
SETTLEMENT AMOUNT	530,000
1776 Curtis Denver, CO [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
ORIGINAL OBLIGATION	1,079,000
1776 Curtis Denver, CO [Member] | Settled Litigation [Member]
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]
SETTLEMENT AMOUNT	$ 348,764

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)				3 Months Ended		12 Months Ended
	May 10, 2024	Apr. 26, 2024	Mar. 19, 2024	Mar. 31, 2024	Mar. 31, 2023	Mar. 19, 2025
Subsequent Events (Details) [Line Items]
Share-Based Payment Arrangement, Noncash Expense (in Dollars)				$ 0	$ 897,933
Stock Issued During Period, Shares, Restricted Stock Award, Gross	300,000	150,000	225,000
Other Affiliates [Member]
Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	75,000	75,000	75,000
Restricted Stock [Member]
Subsequent Events (Details) [Line Items]
Share-Based Payment Arrangement, Noncash Expense (in Dollars)						$ 60,000
Shares Issued, Price Per Share (in Dollars per share)	$ 0.8	$ 0.8	$ 0.80